Cardiologist Cork | ECG & Stress tests Cork (2022)

Biography

Visit my website: www.coscardio.ie

Follow me on Twitter

Connect with me on Linkedin

Cróchángraduated from NUI Galway in 2004 and underwent basic medical training in the Mater Hospital in Dublin and Mayo Clinic, Rochester. He then underwent Cardiology specialist training in the Mater Hospital and St. Vincents Hospital, Dublin. In 2011 he was awarded the Dr. Richard Steeven's Scholarship by the HSE to undertake subspeciality training in Interventional Cardiology and Transcatheter Aortic Valve Implanatation (TAVI) in Bern University Hospital, Switzerland.

He was awarded a research grant by the European Society of Cardiology (ESC) to perform clinical research in TAVI from which he generated over 60 peer reviewed publications and was awarded his PhD in 2015.

In 2014 he was appointed Consultant Interventional Cardiologist at Triemli City Hospital, Zurich and Assistant Professor in Bern University, Switzerland where he worked for 4 years from July 2014 until March 2018. He subsequently spent 3 months performing advanced structural heart interventions at Karolinska University Hospital, Stockholm (minimally invasive TAVI, MitraClip, PFO and ASD Closure, and Cardioband). He is a Fellow of the European Society of Cardiology (FESC) and his practice involves both General and Interventional Cardiology with a special interest in structural heart disease interventions.

Education, Diplomas and Specialization

2017 Assistant Professor, University of Bern, Switzerland (Habilitation)

2016 Fellow of the European Society of Cardiology (FESC)

2015 PhD (Medicine), National University of Ireland Galway, Ireland

2014 MD (Doctor of Medicine), University of Bern

2011 – 2014 Interventional Cardiology Fellowship, Bern University Hospital, Switzerland

2013 Certificate of Satisfactory Completion of Specialist Training (CSCST) Cardiology

2006 Membership of the Royal College of Physicians in Ireland

2005 United States Medical Licensing Examination (USMLE) (Steps 1,2 & 3)

2004 Final Medical Exam, National University of Ireland, Galway, Ireland

2003 Thesis: Thrombin and PAR1-activating peptide: effects on human uterine contractility in vitro.

2002 BSc (Anatomy) – graduated with first class honours

1997 2004 Studied Medicine at the National University of Ireland, Galway, Ireland

Work Experience

Advanced Structural Heart Disease Fellow, Karolinska University Hospital, Stockholm, Sweden:

04/18-06/18: Performed TAVI with newer generation transcatheter heart valves (Accurate Neo using ultrasound guided transfemoral puncture), MitraClip (including NTR and XTR newer generation devices) and Cardioband.

Consultant Interventional Cardiologist Triemli City Hospital, Zürich

07/14-03/18: Triemli City Hospital, Zürich is the highest volume primary PCI centre in Zürich and the second highest volume centre in Switzerland. Performed an average of 500 PCIs per year and was also involved in the structural heart programme including TAVI, LAA Closure and PFO Closure.

Specialisation in Interventional Cardiology (2011 - 2014)

07/13-06/14: Structural heart disease, Inselspital, Bern, Prof. Dr. P. Wenaweser, Prof. Dr. S. Windecker.

09/12-06/13: Invasive cardiology, Inselspital, Bern, 50% catheterization laboratory, 50% clinical research on percutaneous aortic valve replacement, Prof. Dr. P. Wenaweser, Prof. Dr. S. Windecker.

09/11-08/12: Invasive cardiology, Inselspital, Bern, 100% in the catheterization laboratory, Prof. Dr. S. Windecker, Prof. Dr. B. Meier.

General Cardiology Rotations (2007 – 2011)

07/10-08/11 Specialist Registrar, Cardiology, University College Hospital, Galway, Ireland.

07/09-06/10 Specialist Registrar, Cardiology, St. Vincent’s University Hospital, Dublin, Ireland.

07/08-06/09 Specialist Registrar, Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland.

07/07-06/08 Specialist Registrar, Internal Medicine, Wexford General Hospital, Wexford, Ireland.

(Video) Cardiology at Bon Secours Cork

Internal Medicine Rotations (2004 – 2007)

01/07-06/07 Senior house officer, Internal Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.

07/06-12/06 Senior house officer, Internal Medicine, Mayo Clinic, Rochester, MN, USA.

07/05-06/06 Senior house officer, Internal Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.

07/04-06/05 Intern, Medicine and Surgery, University College Hospital, Galway, Ireland.

Grants and Awards

2012 European Association for Percutaneous Coronary Intervention (EAPCI) clinical research grant (€ 25’000).

2011 Dr. Richard Steevens Travelling Scholarship from the Department of Health, Ireland (€ 62’000).

2004 Gold medal in medicine.

2003 Society for Gynecologic Investigation (SGI) und Wyeth Ayerst Pharmaceutical Presidents Presenter Award for the best scientific abstract at the 50th anniversary of the Society for Gynecologic Investigation in Washington, DC, USA, March 25–30, 2003

2000 Pharmacia and Upjohn Gold Medal in Pharmacology Award.

Reviewer Activities

Circulation

Circulation: Cardiovascular Interventions

Journal of the American College of Cardiology

Journal of the American College of Cardiology: Cardiovascular Interventions

Journal of the American College of Cardiology: Imaging

EuroIntervention

Catheter Cardiovascular Interventions

Editorial Board Membership

Interventional Cardiology Review, Radcliffe Cardiology, UK, Editorial Board

Frontiers in Cardiovascular Medicine, Associate Editor

Memberships

European Society of Cardiology

European Association for Percutaneous Coronary Intervention

Irish Cardiac Society

FMH

Swiss Cardiac Society

Zürich Cardiac Society

Publications

Original articles:

Meyer MR, Bernheim AM, Kurz DJ, O’Sullivan CJ, Tuller D, Zbinden R, Rosemann T, Eberli FR. Gender differences in patient and system delay for primary percutaneous coronary intervention: current trends in a Swiss ST-segment elevation myocardial infarction population. Eur Heart J Acute Cardiovasc Care. 2019;8(3):283-290. PMID 30406673.

O’Sullivan CJ, Montalbetti M, Zbinden R, Kurz DJ, Bernheim AM, Liew A, Meyer MR, Tüller D, Eberli FR. Screening for pulmonary hypertension with multidetector computed tomography among patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. Front Cardiovasc Med. 2018.5;5:63. PMID:29951486.

(Video) Bon Secours Hospital Cork - Cardiology department

Pilgrim T, Lee JKT, O'Sullivan CJ, Stortecky S, Ariotti S, Franzone A, Lanz J, Heg D, Asami M, Praz F, Siontis GCM, Vollenbroich R, Räber L, Valgimigli M, Roost E, Windecker S. Early versus newer generation devices for transcatheter aortic valve implantation in routine clinical practice: a propensity score matched analysis. Open Heart. 2018 Jan 20;5(1):e000695. PMID 29387427.

Yamaji K, Ueki Y, Souteyrand G, Daemen J, Wiebe J, Nef H, Adriaenssens T, Loh JP, Lattuca B, Wykrzykowska JJ, Gomez-Lara J, Timmers L, Motreff P, Hoppmann P, Abdel-Wahab M, Byrne RA, Meincke F, Boeder N, Honton B, O’Sullivan CJ, Lelasi A, Delarche N, Christ G, Lee JKT, Lee M, Amabile N, Karagiannis A, Windecker S, Räber L. Mechanisms of Very Late Bioresorbable Scaffold Thrombosis: The INVEST Registry. J Am Coll Cardiol. 2017;70(19):2330-2344. PMID: 29096803.

Franzone A, O’Sullivan CJ, Stortecky S, Heg D, Lanz J, Vollenbroich R, Praz F, Piccolo R, Asami M, Roost E, Räber L, Vlalgimigli M, Windecker S, Pilgrim T. Prognostic impact of invasive haemodynamic measurements in combination ith clinical and echocardiographic characteristics on two-year clinical outcomes of patients undergoing transcatheter aortic valve implantation. EuroIntervention 2017;12(18):e2186-e2193. PMID:28117283.

Vollenbroich R, Stortecky S, Praz F, Lanz J, Franzone A, Zuk K, Heg D, Valgimigli M, O’Sullivan CJ, Heinisch C, Roost E, Wenaweser P, Windecker S, Pilgrim T. The impact of functional vs degererative mitral regurgitation on clinical outcomes among patients undergoing transcatheter aortic valve implantation. Am Heart J. 2017;184:71-80. PMID:27892889.

O’Sullivan CJ, Spitzer E, Heg D, Praz F, Stortecky S, Huber C, Carrel T, Pilgrim T, Windecker S. Effect of resting heart rate on two-year clinical outcomes of high-risk patients with severe symptomatic aortic stenosis undergoing transcatheter aortic valve implantation. EuroIntervention 2016;12(4):490-8. PMID:27436601.

Koskinas KC, Stortecky S, Franzone A, O’Sullivan CJ, Praz F, Zuk K, Räber L, Pilgrim T, Moschovitis A, Fiedler GM, Jüni P, Heg D, Wenaweser P, Windecker S. Post-procedural troponin elevation and clinical outcomes following transcatheter aortic valve implantation. J Am Heart Assoc. 2016;5(2):e002430. PMID:26896474.

Räber L, Brugaletta S, Yamaji K, O’Sullivan CJ, Otsuki S, Kopara T, Taniwaki M, Onuma Y, Freixa X, Eberli FR, Serruys PW, Joner M, Sabatè M, Windecker S. Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings. J Am Coll Cardiol. 2015;66(17):1901-14. PMID:26493663.

Koskinas KC, O’Sullivan CJ, Heg D, Praz F, Stortecky S, Pilgrim T, Buellesfeld L, Jüni P, Windecker S, Wenaweser P. Effect of B-type natriuretic peptides on long-term outcomes after transcatheter aortic valve implantation. Am J Cardiol. 2015;116(10):1560-5. PMID:26428025.

O’Sullivan CJ, Wenaweser P, Ceylan O, Rat-Wirtzler J, Stortecky S, Heg D, Spitzer E, Zanchin T, Praz F, Tüller D, Huber C, Pilgrim T, Nietlispach F, Khattab AA, Carrel T, Meier B, Windecker S, Buellesfeld L. Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interv. 2015;8(7):e002358. PMID:26156149.

O’Sullivan CJ, Englberger L, Hosek N, Heg D, Cao D, Stefanini GG, Stortecky S, Gloekler S, Spitzer E, Tüller D, Huber C, Pilgrim T, Praz F, Buellesfeld L, Khattab AA, Carrel T, Meier B, Windecker S, Wenaweser P. Clinical outcomes and revascularization strategies in patients with low-flow, low-gradient severe aortic valve stenosis according to the assigned treatment modality. JACC Cardiovasc Interv. 201;8(5):704-17. PMID:25946444.

Huber C, Praz F, O’Sullivan CJ, Langhammer B, Gloekler S, Stortecky S, von Allmen RS, Meier B, Carrel T, Englberger L, Windecker S, Wenaweser P. Transcarotid aortic valve-in-valve implantation for degenerated stentless aortic root conduits with severe regurgitation: a case series. Interact Cardiovasc Thorac Surg. 2015;20(6):694-700. PMID:25776924.

O’Sullivan CJ, Stortecky S, Bütikofer A, Heg D, Zanchin T, Huber C, Pilgrim T, Praz F, Buellesfeld L, Khattab AA, Blöchlinger S, Carrel T, Meier B, Zbinden S, Wenaweser P, Windecker S. Impact of mitral regurgitation on clinical outcomes of patients with low-ejection fraction, low-gradient severe aortic stenosis undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv. 2015;8(2):e001895. PMID:25657315.

Mylotte D, Lefevre T, Sondergaard L, Wantanabe Y, Modine T, Dvir D, Bosmans J, Tchetche D, Kornowski R, Sinning JM, Thèriault-Lauzier P, O’Sullivan CJ, Barbanti M, Debry N, Buithieu J, Codner P, Dorfmeister M, Martucci G, Nickenig G, Wenaweser P, Tamburino C, Grube E, Webb JG, Windecker S, Lange R, Piazza N. J Am Coll Cardiol. 2014;64(22):2330-9. PMID:5465419.

Rothenbühler M, O’Sullivan CJ, Stortecky S, Stefanini GG, Spitzer E, Estill J, Shrestha NR, Keiser O, Jüni P, Pilgrim T. Active surveillance for rheumatic heart disease in endemic regions: a systematic review and meta-analysis of prevalence among children and adolescents. Lancet Glob Health. 2014;2(12):e717-26. PMID:25433627.

Pilgrim T, Englberger L, Rothenbühler M, Stortecky S, Ceylan O, O’Sullivan CJ, Huber C, Praz F, Buellesfeld L, Langhammer B, Meier B, Jüni P, Carrel T, Windecker S, Wenaweser P. Long-term outcome of elderly patients with severe aortic stenosis as a function of treatment modality. Heart 2015;101(1):30-6. PMID:25163691.

Khattab AA, Gloekler S, Sprecher B, Shakir S, Guerios E, Stortecky S, O’Sullivan CJ, Nietlispach F, Moschovitis A, Pilgrim T, Buelesfeld L, Wenaweser P, Windecker S, Meier B. Feasibility and outcomes of combined transcatheter aortic valve replacement with other structural heart interventions in a single session: a matched cohort study. Open Heart 2014;1(1):e000014. PMID:25332781.

Stefanini GG, Stortecky S, Cao D, Rat-Wirtzler J, O’Sullivan CJ, Gloekler S, Buellesfeld L, Khattab AA, Nietlispach F, Pilgrim T, Huber C, Carrel T, Meier B, Jüni P, Wenaweser P, Windecker S. Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation. Eur Heart J. 2014;35(37):2530-40. PMID:24682843.

O’Sullivan CJ, Stortecky S, Heg D, Jüni P, Windecker S, Wenaweser P. Impact of B-type natriuretic peptide on short-term clinical outcomes following transcatheter aortic valve implantation. EuroIntervention. 2015;10(10):e1-8. PMID:24429160.

O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Zanchin T, Hosek N, Gloekler S, Meier B, Windecker S, Wenaweser P. Clinical Outcomes Of Patients with Low Flow, Low Gradient, Severe Aortic Stenosis and Either Preserved or Reduced Ejection Fraction Undergoing Transcatheter Aortic Valve Implantation. Eur Heart J. 2013;Nov;34(44):3437-50. PMID:24096324

O’Sullivan CJ, Stefanini GG, Räber L, Heg D, Taniwaki M, Kalesan B, Pilgrim T, Zanchin T, Moschovitis A, Büllesfeld L, Khattab AA, Meier B, Wenaweser P, Jüni P, Windecker S. Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug eluting stents. EuroIntervention 2014;9(9):1076-84. PMID:24064474.

Wenaweser P, Stortecky S, Schwander S, Heg D, Huber C, Pilgrim T, Gloekler S, O'Sullivan CJ, Meier B, Jüni P, Carrel T, Windecker S. Clinical Outcomes of Patients with Estimated Low or Intermediate Surgical Risk Undergoing Transcatheter Aortic Valve Implantation. Eur Heart J. 2013 Jul;34(25):1894-905. PMID:23487519.

Khattab AA, O'Sullivan CJ, Stefanini GG, Räber L, Paquin M, Windecker S, Meier B. New Approach to Direct Stenting using a Novel 'All-In-One' Coronary Stent System via 5 French Diagnostic Catheters: A Pilot Study. Catheter Cardiovasc Interv. 2013;82(4):E403-10. PMID:23378279.

Doyle BJ, Rihal CS, O’Sullivan CJ, Lennon RJ, Wiste HJ, Bell M, Bresnahan J, Holmes DR. Outcomes of Stent Thrombosis and Restenosis during Extended Follow Up of Patients Treated with Bare-Metal Coronary Stents. Circulation. 2007;116:2391-2398. PMID:17984377.

O’Sullivan CJ, Hynes N, Mahendran M, Andrews EJ, Avalos G, Tawfik S, Sultan S. Haemoglobin A1c (HbA1c) in Non-diabetic and Diabetic Vascular Patients. Is HbA1c an Independent Risk Factor and Predictor of Adverse Outcome? European Journal of Vascular and Endovascular Surgery. 2006 Aug;32(2):188-197. PMID:16580235.

O’Loughlin AJ, O’Sullivan CJ, Ravikumar N, Friel AM, Elliott JT, Morrison JJ. Effects of Thrombin, PAR-1 Activating Peptide and a PAR-1 Antagonist on Umbilical Artery Resistance in vitro. Reproductive Biology and Endocrinology. 2005 Feb 24;3(1):8. PMID:15730558.

O’Sullivan CJ, Allen NM, O’Loughlin AJ, Friel AM, Morrison JJ. Thrombin and PAR1-Activating Peptide: Effects on Human Uterine Contractility in vitro.
American Journal of Obstetrics and Gynecology. 2004 Apr;190(4):1098-105. PMID:15118649

Review articles

De Palma R, O’Sullivan CJ, Settergren M. Is there currently a place for combined mitral and aortic transcatheter interventions? Curr Cardiol Rep. 2019;21(10):129. PMID: 31520150.

O’Sullivan CJ, Wenaweser P. A glimpse into the future: In 2020, which patients will undergo TAVI or SAVR? Interventional Cardiology Review. 2017;12(1):44-50.

O’Sullivan CJ, Tüller D, Zbinden R, Eberli FR. Impact of mitral regurgitation on clinical outcomes after transcatheter aortic valve implantation. Interventional Cardiology Review. 2016;11(1):54-8.

O’Sullivan CJ, Wenaweser P. Optimizing clinical outcomes of transcatheter aortic valve implantation patients with comorbidities. Expert Rev Cardiovasc Ther. 2015;13(12):1419-32. PMID:26479904.

O’Sullivan CJ, Stefanini GG, Stortecky S, Tüller D, Windecker S, Wenaweser P. Coronary revascularization and TAVI: before, during, after or never? Minerva Med. 2014;105(6):475-85. PMID:25274461.

O’Sullivan CJ, Praz F, Stortecky S, Windecker S, Wenaweser P. Assessment of low-flow, low-gradient, severe aortic stenosis: an invasive evaluation is required for decision making. EuroIntervention. 2014;10 Suppl U:U61-8. PMID:25256333.

(Video) Sudden Cardiac Arrest: Saving Lives When Every Second Counts

O’Sullivan CJ, Stortecky S, Buellesfeld L, Wenaweser P, Windecker S. Preinterventional Screening of the TAVI Patient: How to Choose the Suitable Patient and the Best Procedure. Clinical Research in Cardiology. 2014:103(4):259-74. PMID 24515650.

Stortecky S, O’Sullivan CJ, Buellesfeld L, Wenaweser P, Windecker S. Transcatheter Aortic Valve Implantation: Patient Selection.
Minerva Cardioangiologica. 2013 Oct;61(5):487-497. PMID: 24096244

Stortecky S, O’Sullivan CJ, Buellesfeld L, Windecker S, Wenaweser P. Transcatheter Aortic Valve Implantation: The Transfemoral Access Route is the Default Access. EuroIntervention. 2013 Sep 10;9 Suppl:S14-8. PMID:24025952

Editorials

O'Sullivan CJ, Spitzer E. Transaortic flow rate versus stroke volume index in low-gradient aortic stenosis. JACC:Cardiovascular Imaging 2019;12(9):1725-1727. PMID 29550325.

O’Sullivan CJ, Wenaweser P. Can we predict quality of life and survival after transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2015;8(12):e003347. PMID:26643742.

O’Sullivan CJ, Eberli FR. Left ventricular thrombus formation after acute myocardial infarction. Vigilance still required in the modern era. Swiss Med Wkly. 2015;145:w14158. PMID:26099039.

O’Sullivan CJ, Wenaweser P. Reclassification of low-gradient aortic stenosis severity in patients with preserved ejection fraction: when is severe truly severe? Eur Heart J.2015;36(31):2039-2041. PMID:26040798.

O’Sullivan CJ, Wenaweser P. Low-flow, low-gradient aortic stenosis: should TAVI be the default therapeutic option? EuroIntervention. 2014;10(7):775-7. PMID:25414144.

Windecker S, O’Sullivan CJ. Mitigating the risk of early stent thrombosis.
J Am Coll Cardiol. 2014;63(23):2521-4. PMID:24768885.

O’Sullivan CJ, Windecker S. Implications of Bicuspid Aortic Valves for Transcatheter Aortic Valve Implantation. Circ Cardiovasc Interv. 2013;6(3):204-6. PMID:23780294.

O’Sullivan CJ, Windecker S. Peri-procedural myocardial infarction: time for re-evaluation of its definition and use as an endpoint in coronary stent trials.
Heart. 2012;98(19):1397-1399. PMID:22965793.

O’Sullivan CJ, Wenaweser P. Aortic stenosis and the right heart at risk: Is transcatheter aortic valve implantation the better option? Heart. 2012;98(17):1265-6. PMID:22875821.

Case reports

O’Sullivan CJ, Groza D, Eberli FR. Left ventricular pseudoaneurysm formation in a patient presenting with a subacute myocardial infarction. BMJ Case Report. 2017;pii: bcr-2017-222481. doi: 10.1136/bcr-2017-222481. PMID 29246934

O’Sullivan CJ, Kurz DJ. An unusual cause of cardiac tamponade following pericardial window formation. Acta Cardiologica. 2017

O’Sullivan CJ, Magarzo JG, Bernheim AM, Eberli FR. Paradoxical embolism via a sinus venosus atrial septal defect causing an inferior ST-segment elevation myocardial infarction in a 23-year-old woman. BMJ Case Rep. 2016;pii:bcr2016215184. PMID: 27130557.

O’Sullivan CJ, Bühlmann Lerjen E, Pellegrini D, Eberli FR. Sudden cardiac arrest during emergency caesarean delivery in a 31-year-old woman, due to accelerated structural valve degeneration of an aortic valve bioprosthesis. BMJ Case Rep. 2015. Pii:bcr2015212575. PMID:26568057.

O’Sullivan CJ, Sprenger M, Tueller D, Eberli FR. Coronary thromboembolic acute myocardial infarction due to paroxysmal atrial fibrillation occurring after non-cardiac surgery. BMJ Case Rep. 2015;2015.pii:bcr2014208329. PMID:25814175.

O’Sullivan CJ, Meier B. Left Main Coronary Stent Positioning using Rapid Transcoronary Pacing. Journal of Invasive Cardiology 2013 Jan;25(1):E4-7.PMID:23293185.

Letters to the editor

O’Sullivan CJ, Wenaweser P, Ceylan O, Stortecky S, Spitzer E, Zanchin T, Praz F, Pilgrim T, Khattab AA, Meier B, Windecker S, Buellesfeld L, Tüller D, Rat-Wirtzler J, Heg D, Huber C, Carrel T, Nietlispach F. Response to letter regarding article, „Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: Insights from the new proposed pulmonary hypertension classification“. Circ Cardiovasc Interv. 2015;8(9):e003064. PMID:26330389.

O’Sullivan CJ, Stortecky S, Wenaweser P. Invasive Hemodynamic Characteristics of Paradoxical Low Flow, Low Gradient Aortic Stenosis.
J Am Coll Cardiol 2013 Oct 15;62(16):1492-1493. PMID:23892253

Book chapters

O’Sullivan CJ, Meier B. Transcoronary Pacing. Urgent Interventional Therapies. Kipshidze N, Fareed J, Rosen RT, Serruys P. October 2014, Wiley-Blackhall. ISBN: 978-0-470-67202-0.

Abstracts (Selected)

O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Zanchin T, Hosek N, Gloekler S, Meier B, Windecker S, Wenaweser P. Clinical outcomes among patients with low flow, low gradient, severe aortic stenosis according to treatment modality. J Am Coll Cardiol 2013;62(18_S1):B217-B217

O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Zanchin T, Hosek N, Gloekler S, Meier B, Windecker S, Wenaweser P. Clinical Outcomes among patients with low-flow, low-gradient, severe aortic stenosis with either preserved or reduced ejection fraction undergoing transcatheter aortic valve replacement. Ir J Med Sci 2013;182(Suppl 8):S359-S392.

O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Zanchin T, Hosek N, Gloekler S, Meier B, Windecker S, Wenaweser P. Clinical outcomes among patients with low flow, low gradient, severe aortic stenosis according to treatment modality. EuroIntervention Supplement 2013;9 London abstracts.

O’Sullivan CJ, Stortecky S, Hosek N, Ceylan O, Gloekler S, Büllesfeld L, Meier B, Windecker S, Wenaweser P. Impact of B-type natriuretic peptide on clinical outcomes among patients undergoing transcatheter aortic valve implantation. European Heart Journal 2013;34(Suppl 1):993

O’Sullivan C, Stortecky S, Hosek N, Huber C, Pilgrim T, Khattab A, Gloekler S, Nietlispach F, Buellesfeld L, Meier B, Carrel T, Windecker S, Wenaweser P. Prevalence, invasive haemodynamic characteristics and clinical outcomes of patients with “paradoxical” low flow, low gradient severe aortic stenosis with preserved ejection fraction undergoing TAVI. EuroIntervention Supplement 2013:139.

Steffanini GG, Taniwaki M, Räber L, Cao D, Pilgrim T, Stortecky S, O’Sullivan CJ, Wenaweser P, Meier B, Jüni P, Windecker S. Stent thrombosis with zotarolimus-eluting resolute stents compared with everolimus-eluting stents: an updated meta-analysis of randomised clinical trials. EuroIntervention Supplement 2013:98.

O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Zanchin T, Hosek N, Gloekler S, Meier B, Windecker S, Wenaweser P. Clinical Outcomes among patients with low-flow, low-gradient, severe aortic stenosis with either preserved or reduced ejection fraction undergoing transcatheter aortic valve replacement: An invasive hemodynamic study. J Am Coll Cardiol. 2013;61(10):A495

(Video) Safety and Efficacy of Using Insulin-Like Growth Factor-1 in Heart Attack

O’Sullivan CJ, Stefanini G, Räber L, Heg D, Taniwaki M, Kalesan B, Pilgrim T, Zanchin T, Moschovitis A, Büllesfeld L, Khattab AA, Wanaweser P, Meier B, Jüni P, Windecker S. Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents. J Am Coll Cardiol. 2012;60(17):B175

O’Sullivan CJ, Moschovitis A, Zanchin T, Stortecky S, Stefanini G, Pilgrim T, Räber L, Taniwaki M, Büllesfeld L, Khattab A, Nietlispach F, Wenaweser PM, Meier B, Windecker S. Long-term clinical outcomes of percutaneous coronary intervention with drug-eluting stents in patients with mechanical heart valves. Cardiovascular Medicine 2012;15(5):Suppl 21:43

O’Sullivan CJ, Andrews EJ, Mahendran B, Hynes N, Avalos G, Tawfik S, Lowery A, Sultan S. Is HbA1c an independent risk factor and predictor of adverse outcome in diabetic and non-diabetic vascular patients? Irish Journal of Medical Science January, February, March 2006:175(1)S2:34

O’Sullivan CJ, Hynes N, Mahendran M, Tawfik S, Tawfik W, Courtney D, Sultan S. HbA1c as an independent risk factor and predictor of adverse outcome in diabetic and non-diabetic vascular patients: A prospective cross-over study with primary composite end-point. Irish Journal of Medical Science January, February, March 2006:175(1)S1:16.

O’Sullivan CJ, Sultan S, Andrews E, Hynes N, Mahendran M, Ishtiaq A, Courtney D. Haemoglobin A1C (HBA1C) in nondiabetic vascular patients. Is HBA1C an independent risk factor and predictor of adverse outcome? European Society for Vascular Surgery, Programme and Abstract Book, September 2005: page 94.

O’Sullivan CJ, Andrews E, Mahendran M, Hynes N, Ishtiaq A, Sultan S. Haemaoglobin A1c (HbA1c) in nondiabetic vascular patients. Is HbA1c an independent risk factor and predictor of adverse outcome? Irish Journal of Medical Science September 2005:174(3)S1:49.

O’Sullivan CJ,Andrews E, Mahendran M, Hynes N, Ishtiaq A, Sultan S. Haemoglobin A1C (HbA1c) in nondiabetic vascular patients is an independent risk factor and predictor of adverse outcome. A cohort study. Vascular Annual Meeting Chicago, IL, Scientific Program, June 2005: page 74.

O’Sullivan CJ, O’Loughlin AJ, Friel AM, Elliot JT, Morrison JJ. PAR function in the human pregnant myometrium: Effects of Thrombin and Specific PAR-1 Agonist and Antagonist. Journal of the Society for Gynecologic Investigation March 2003:10(2)299A.

O’Loughlin AJ, O’Sullivan CJ, Ravikumar N, Friel AM, Elliot JT, Morrison JJ. Effects of Thrombin, PAR-1 Agonist, and PAR-1 Antagonist on Umbilical Artery Resistance in vitro. Journal of the Society for Gynecologic Investigation March 2003:10(2)299A.

O’Sullivan CJ, Allen NM, O’Loughlin AJ, Friel AM, Elliot JT, Morrison JJ. PAR Function in Human Pregnant Myometrium: Effects of Thrombin and Specific PAR-1 Agonist and Antagonist. British Journal of Obstetrics and Gynecology 2003 Oct;110(10):962.

O’Sullivan CJ, O’Loughlin AJ, Friel AM, Elliot JT, Morrison JJ. PAR function in the human pregnant myometrium: Effects of Thrombin and Specific PAR-1 Agonist and Antagonist. Galway Medical Annual 2003.

Presentations (Selected)

London, United Kingdom. PCR London Valves 2013. O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Zanchin T, Hosek N, Gloekler S, Meier B, Windecker S, Wenaweser P. Clinical outcomes among patients with low flow, low gradient, severe aortic stenosis according to treatment modality (Oral presentation).

Amsterdam, Netherlands. European Society of Cardiology 2013. O’Sullivan CJ, Stortecky S, Hosek N, Ceylan O, Gloekler S, Büllesfeld L, Meier B, Windecker S, Wenaweser P. Impact of B-type natriuretic peptide on clinical outcomes among patients undergoing transcatheter aortic valve implantation (Poster presentation)

Paris, France. EuroPCR 2013. O’Sullivan C, Stortecky S, Hosek N, Huber C, Pilgrim T, Khattab A, Gloekler S, Nietlispach F, Buellesfeld L, Meier B, Carrel T, Windecker S, Wenaweser P. Prevalence, invasive haemodynamic characteristics and clinical outcomes of patients with “paradoxical” low flow, low gradient severe aortic stenosis with preserved ejection fraction undergoing TAVI (Oral Presentation).

San Francisco, USA (March 9-11, 2013) American College of Cardiology 2013 annual meeting. O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Zanchin T, Hosek N, Gloekler S, Meier B, Windecker S, Wenaweser P. Clinical Outcomes among patients with low-flow, low-gradient, severe aortic stenosis with either preserved or reduced ejection fraction undergoing transcatheter aortic valve replacement: An invasive hemodynamic study (Oral presentation).

Miami, USA (October 22-26, 2012) Transcatheter Cardiovascular Therapeutics Meeting: O’Sullivan CJ, Stefanini G, Räber L, Heg D, Taniwaki M, Kalesan B, Pilgrim T, Zanchin T, Moschovitis A, Büllesfeld L, Khattab AA, Wanaweser P, Meier B, Jüni P, Windecker S. Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents (TCT-605) (Poster)

Lausanne, Switzerland (June 2012) Swiss Cardiology Society: . Long-term Clinical Outcomes of Percutaneous Coronary Intervention with Drug-Eluting Stents in Patients with Mechanical Heart Valves (Oral presentation)

San Francisco, USA (November 7-11, 2011) Transcatheter Cardiovascular Therapeutics Meeting: O’Sullivan CJ et al. Which is the Culprit? Complex Revascularization in a 63-Year-Old Male with Previous Coronary Artery Bypass Grafting Presenting with Non-ST-Segment Elevation Myocardial Infarction (TCT-1012) (presented in the Challenging Cases Video Abstracts section)

Paris, France (May 17-20, 2011) EuroPCR: O’Sullivan CJ et al. The Coronary Guide Wire Won’t Come Back. (Presented in the Interactive Case Corner Section).

Helsinki, Finland (September 16-19, 2005): European Society for Vascular Surgery (ESVS) 19th Annual Meeting. O’Sullivan CJ, Sultan S, Andrews E, Hynes N, Mahendran M, Ishtiaq A, Courtney D. Haemoglobin A1C (HBA1C) in nondiabetic vascular patients. Is HBA1C an independent risk factor and predictor of adverse outcome? (Short-listed for Prize)

Chicago, Illinois, US (June 16-19, 2005): Society of Vascular Surgery (SVS) 2005 Annual Meeting. O’Sullivan CJ, Andrews E, Mahendran M, Hynes N, Istiaq A, Sultan S. Haemoglobin A1c (HbA1c) in nondiabetic and diabetic vascular patients is an independent risk factor and predictor of adverse outcome. A cohort study.

Berlin, Germany (June 3-4, 2005): Vascular Biology Working Group European Chapter Meeting. O’Sullivan CJ, Mahendran M, Sultan S. Haemoglobin A1c (HbA1c) in non-diabetic and diabetic vascular patients. Is HbA1c an independent risk factor and predictor of adverse outcome?

Glasgow, Scotland, UK (June 4-5, 2003): Combined Blair Bell/Munro-Kerr Society Meeting, Glasgow Royal Infirmary. O’Sullivan CJ, Allen NM, O’Loughlin AJ, Friel AM, Elliot JT, Morrison JJ. PAR Function in the Human Pregnant Myometrium: Effects of Thrombin and Specific PAR-1 Agonist and Antagonist.

Washington DC, US (March 25-30, 2003): 50th Anniversary Meeting of the Society for Gynecologic Investigation (SGI). O’Sullivan CJ, O’Loughlin AJ, Friel AM, Elliot JT, Morrison JJ. PAR function in the human pregnant myometrium: Effects of Thrombin and Specific PAR-1 Agonist and Antagonist.

Areas of Interest

Special Interests Include:

  • Complex Percutaneous Coronary Intervention

  • Chronic Total Occlusions

  • Patent Foramen Ovale and Atrial Septal Defect closure

  • Left Atrial Appendage Occlusion

  • Transcatheter Aortic Valve Implanation

Qualifications

BSc. (Hons), MD, PhD, FESC

Appointments

Referral & Enquiries Email:

(Video) Chest Pain in 40 year old -- Is It Serious?

admin@coscardio.ie

FAQs

Can a stress echo detect blockages? ›

Your doctor might recommend a stress echocardiogram to check for coronary artery problems. However, an echocardiogram can't provide information about any blockages in the heart's arteries.

What types of stress test? ›

There are three main types of stress tests: exercise stress tests, nuclear stress tests, and stress echocardiograms. All types of stress tests may be done in a health care provider's office, outpatient clinic, or hospital.

What is a jelly test for the heart? ›

This is a painless procedure that is usually performed in hospital or in an outpatient clinic. You'll have jelly applied to your bare chest, and an experienced operator will move the probe around your chest to get good views of your heart. It can check: the size of the heart.

What do they do in cardiology? ›

Cardiologists diagnose, assess and treat patients with defects and diseases of the heart and the blood vessels, which are known as the cardiovascular system.

Does stress test show all heart problems? ›

But stress testing doesn't accurately diagnose all cases of CAD, and sometimes it points to CAD in people who do not actually have the condition. "The test result is never, by itself, certain," Dr. Bhatt says. "It can be used to move the probability up or down of there being coronary artery disease.

What happens if a stress test shows a blockage? ›

If blood isn't flowing well, you may have a blockage in one or more of the coronary arteries of your heart. In that case, you may need to have another test, or an angiography, stent or heart bypass surgery to open up a blocked artery.

Why would a cardiologist order a stress test? ›

Your doctor may recommend a stress test if you have signs or symptoms of coronary artery disease or an abnormal heart rhythm (arrhythmia). A stress test can help: Guide treatment decisions. Determine how well heart treatment is working.

What test is better than a stress test? ›

Johns Hopkins Medicine. Heart CT scans outperform stress tests in spotting clogged arteries [press release].

What is a good score on a stress test? ›

Low risk (score > 5) indicates a 5-year survival of 97%. Intermediate risk (score between 4 and -11) indicates 5-year survival of 90%. High risk (score < -11) indicates 5-year survival of 65%. In high-risk patients, 74% had 3-vessel or left main occlusive coronary disease on angiography.

What will a cardiologist do on your first visit? ›

Complete a Physical Examination

Your cardiologist might complete a medical examination. This includes checking your weight and testing for high blood pressure, high cholesterol, and other risk factors for heart disease.

What should I expect at my first cardiologist appointment? ›

You will be asked both general health questions and some more specific questions related to the reason for your visit. A physical examination follows, and if necessary the doctor might arrange for further testing. The cardiologist might prescribe medication or provide your primary care provider with recommendations.

Why do cardiologists look at your neck? ›

Finally, examining your neck can reveal possible circulatory problems. Your healthcare provider uses 2 fingers on each side of your neck to feel your carotid pulses. The right and left carotid arteries supply blood to your brain. Weak pulses could show a problem with the aortic valve or with the aorta.

What test will show heart blockages? ›

A CT coronary angiogram can reveal plaque buildup and identify blockages in the arteries, which can lead to a heart attack. Prior to the test, a contrast dye is injected into the arm to make the arteries more visible. The test typically takes 30 minutes to complete.

What are the symptoms of heart blockage? ›

What are the symptoms of heart block?
  • Fainting, feeling dizzy.
  • Chest pain.
  • Feeling tired.
  • Shortness of breath.
  • Heart palpitations.
  • Rapid breathing.
  • Nausea.
28 May 2021

How long does the average person last on a stress test? ›

The test ends after maintaining your target heart rate long enough to capture readings about heart function, usually about 10 to 15 minutes. Your target heart rate is higher than when at rest and based on your age and fitness level. Technicians may end the test early if you experience severe symptoms or ask to stop.

Can a stress test pick up heart failure? ›

It can also help detect the reason for a patient's heart failure. Stress tests are done to see whether the heart muscle is getting enough blood flow and oxygen when it is working hard (under stress). Types of stress tests include: Nuclear stress test.

How accurate is a cardiac stress test? ›

Bottom line: In a study where every patient gets the same gold standard, the accuracy of stress test is poor, with sensitivity and specificity both less than 80%. This is a systematic review and meta-analysis looking at all types of perfusion imaging.

What percentage of people have heart attacks during a stress test? ›

It's not entirely risk-free, however: About one patient in every 2,500 has a heart attack during the test.

What is a normal blood pressure during a stress test? ›

The normal ranges of blood pressure response to exercise stress testing are as shown in Figure 1. Normal systolic and diastolic responses to exercise stress testing should not exceed 220 and 100 mm Hg, respectively. Systolic blood pressure of >230 mm Hg is generally considered hazardous.

Is 9 minutes on a treadmill stress test good? ›

Irrespective of test findings, however, subsequent cardiac risk is extremely low. Ability to complete a 9-minute Bruce protocol treadmill exercise may itself provide adequate prognostic reassurance for most purposes.

Is a stress test really necessary? ›

You should probably have an EKG and an exercise stress test if you have symptoms of heart disease, such as chest pain, shortness of breath, an irregular heartbeat, or heavy heartbeats. You may also need the tests if you have a history of heart disease. And you may need these tests if you have diabetes or other risks.

Should someone accompany you to a stress test? ›

Friends/family are welcome to accompany you to the office but are not allowed in the testing area due to our privacy policy. Allow approximately 90 minutes for the test. Test results will be communicated to you by your physician.

What are the 3 types of stress tests? ›

Types of Cardiac Stress Tests
  • Electrocardiogram Stress Test. An electrocardiogram (ECG or EKG) stress test uses small adhesive electrode patches that are placed on the chest and connected to an ECG recording device to measure heart function during exercise. ...
  • Echocardiogram Stress Test. ...
  • Nuclear Medicine Stress Test.

How often are stress tests wrong? ›

For a nuclear stress test, the false positive rate is about 10%—so, for every 10 tests that come back abnormal, 1 of those patients don't actually have a significant coronary blockage. There are several reasons for this. First, a nuclear stress test is a perfusion study, not a look at the coronary arteries.

How long can you live with blocked arteries? ›

Many times people live happily with a blocked artery. But with one blocked artery symptoms are a high chance of reduced life expectancy. Asymptomatic patients live up to 3-5 years.

Can an ECG detect a blocked artery? ›

A health care provider might use an electrocardiogram to determine or detect: Irregular heart rhythms (arrhythmias) If blocked or narrowed arteries in the heart (coronary artery disease) are causing chest pain or a heart attack.

Is 7 minutes on a stress test good? ›

“Generally a test should last 8 to 12 minutes, unless it is prematurely stopped due to fatigue or abnormal signs/symptoms. Patients who remain on the treadmill for 7 minutes or longer are in good to excellent physical condition.”

How do I read my stress test results? ›

Possible Conclusions
  1. Positive or abnormal: Doctors may conclude the stress test is positive for cardiac ischemia—meaning the heart muscle wasn't getting adequate oxygenated blood during the stress. ...
  2. Negative or normal: A negative test result lacks any of the things that could trigger a positive conclusion.

What is the speed of treadmill during stress test? ›

At each stage, the gradient and speed of the treadmill are elevated to increase work output, called METS. Stage 1 of the Bruce protocol is performed at 1.7 miles per hour and a 10% gradient. Stage 2 is 2.5 mph and 12%, while Stage 3 goes to 3.4 mph and 14%.

What can a stress echocardiogram detect? ›

Stress echocardiography is a test that uses ultrasound imaging to show how well your heart muscle is working to pump blood to your body. It is most often used to detect a decrease in blood flow to the heart from narrowing in the coronary arteries.

What test shows blockage in heart? ›

A CT coronary angiogram can reveal plaque buildup and identify blockages in the arteries, which can lead to a heart attack. Prior to the test, a contrast dye is injected into the arm to make the arteries more visible. The test typically takes 30 minutes to complete.

Why would a cardiologist order a stress test? ›

A primary reason why a stress test is performed is to assess the patient's blood and oxygen flow to their heart. A stress test can potentially diagnose medical conditions like coronary artery disease. During a stress test, a patient may have an irregular heartbeat or their heart rate might speed up or slow down.

What is a good score on a stress test? ›

Low risk (score > 5) indicates a 5-year survival of 97%. Intermediate risk (score between 4 and -11) indicates 5-year survival of 90%. High risk (score < -11) indicates 5-year survival of 65%. In high-risk patients, 74% had 3-vessel or left main occlusive coronary disease on angiography.

What are the symptoms of minor heart blockage? ›

If a person has a heart block, they may experience the following symptoms:
  • Lightheadedness or dizziness.
  • Palpitations (skipping, fluttering or pounding in the chest)
  • Fatigue.
  • Chest pressure or pain.
  • Shortness of breath.
  • Fainting spells.
  • Difficulty in doing exercise, due to the lack of blood being pumped around the body.
2 Aug 2018

How long can you live with blocked arteries? ›

Many times people live happily with a blocked artery. But with one blocked artery symptoms are a high chance of reduced life expectancy. Asymptomatic patients live up to 3-5 years.

How can I check my own heart blockage at home? ›

Official answer. You can check for heart disease at home by measuring your pulse rate and your blood pressure if you have a blood pressure monitor. You can also monitor yourself for symptoms of heart disease, such as: Chest pain, pressure, discomfort, or tightness.

Videos

1. What Happens During a Heart Attack
(Mercy Cedar Rapids)
2. 2016 Gothenburg Presentation - Outcomes To Measure Effective Improvement
(International Forum on Quality and Safety in Healthcare)
3. Tachycardia: Fast Heart Rate Symptoms and Treatments with Dr. David Cork | San Diego Health
(Scripps Health)
4. BCH Lecture: Innovative Treatments for Atrial Fibrillation
(Boulder Community Health)
5. AL Garhoud Private Hospital
(Al Garhoud Private Hospital)
6. Imaging in COVID-19
(Konoz Retaj)

Top Articles

You might also like

Latest Posts

Article information

Author: Nicola Considine CPA

Last Updated: 11/12/2022

Views: 6243

Rating: 4.9 / 5 (69 voted)

Reviews: 92% of readers found this page helpful

Author information

Name: Nicola Considine CPA

Birthday: 1993-02-26

Address: 3809 Clinton Inlet, East Aleisha, UT 46318-2392

Phone: +2681424145499

Job: Government Technician

Hobby: Calligraphy, Lego building, Worldbuilding, Shooting, Bird watching, Shopping, Cooking

Introduction: My name is Nicola Considine CPA, I am a determined, witty, powerful, brainy, open, smiling, proud person who loves writing and wants to share my knowledge and understanding with you.